Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 39

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 39
---
 Desai and Itri
Transition Agreement and Release with Neil Desai, Ph.D.

Dr. Desai terminated employment as our Executive Chairman, effective as of October 1, 2024.

Pursuant to the terms of a Transition Agreement and Release entered into between Dr. Desai and the Company, dated October 16, 2024, Dr. Desai became eligible to receive the following: (i) continuing payments of severance pay in the aggregate amount of $1,072,539, payable over a period of 18 months, (ii) payment of COBRA premiums for up to 18 month from the date of termination, and (iii) accelerated vesting of equity awards subject solely to service-based vesting as to the number of shares subject to such awards that would have otherwise vested had Dr. Desai continued to be employed by the Company for an additional 18 months following termination of Dr. Desai’s employment, and (iv) Dr. Desai’s outstanding stock option awards will remain exercisable until the earlier of (a) 12 months following the date of Dr. Desai’s termination of employment or (b) the expiration of the term of such stock option award set forth in the applicable stock option agreement.

Additionally, effective as of October 1, 2024, Dr. Desai became eligible to receive compensation pursuant to the terms of our Outside Director Compensation Policy. Dr. Desai will continue to vest in his outstanding Company equity awards in accordance with their terms for the duration of time that he continues to serve as a member of our board of directors.

Transition Agreement and Release and Consulting Agreement with Loretta Itri, M.D.

Dr. Itri terminated employment as our Chief Medical Officer, effective as of October 1, 2024.

Pursuant to the terms of a Transition Agreement and Release entered into between Dr. Itri and the Company, dated September 16, 2024, Dr. Itri became eligible to receive the following: (i) continuing payments of severance pay for a period of 12 months

<div align='center'>23</div>

equal to the sum of (A)(x) 100% of Dr. Itri’s base salary rate, as in effect on the date of termination, plus (y) 100% of Dr. Itri’s target bonus for 2024 (which will not be prorated for partial 2024 service), divided by (B) 12 (or,